In conclusion, Lynch syndrome patients should not be exposed to TMZ, which is paradoxically a strong risk factor for tumor development, as it selects for and causes expansion of highly tumorigenic Msh2-deficient cells in this therapeutic setting. The gene discussed is MSH2; the disease is Lynch syndrome.